Junho Chung

USPTO Granted Patents = 19 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 60(Granted Patents)

Location History:

Seoul, KR (2004 - 2011)
Seongnam, KR (2019)
Gyeonggi-do, KR (2017 - 2021)
Seongnam-si, KR (2018 - 2024)

Company Filing History:

10 out of 1,557

Seoul National University

patents

4 out of 18

Neuracle Science Co., Ltd.

patents

2 out of 222

National Cancer Center

The Asan Foundation, University of Ulsan Foundation for Industry Cooperation

patent

6. 1 out of 177

Ewha University-Industry Collaboration Foundation

patents

7. 1 out of 321

Korea Research Institute of Bioscience and Biotechnology

patents

8. 1 out of 10

Institut Pasteur Korea

patents

9. 1 out of 197

Oklahoma Medical Research Foundation

patents

10. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12415851 - Monoclonal antibodies to ELTD1 and uses thereof (2025-09-16),

2. 12202889 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2025-01-21),

3. 12098206 - PDGF receptor antibody and use thereof (2024-09-24),

4. 12077599 - Anti-ROS1 antibody and use thereof (2024-09-03),

5. 11970532 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2024-04-30),

6. 11707486 - Natural killer cell expressing anti-cotinine chimeric antigen receptor (2023-07-25),

7. 11618783 - Anti-FAM19A5 antibodies and uses thereof (2023-04-04),

8. 11478555 - Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof (2022-10-25),

9. 11339210 - Anti-C5 antibodies and methods of treating complement-related diseases (2022-05-24),

10. 11332521 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2022-05-17),

11. 11167037 - Antibody drug conjugate platform using bispecific antibody (2021-11-09),

12. 10947299 - Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same (2021-03-16),

13. 10457741 - Chicken antibody transformed into cysteine and site-specific conjugation using same (2019-10-29),

14. 10280215 - Anti-C5 antibodies and methods of treating complement-related diseases (2019-05-07),

15. 9867886 - Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof (2018-01-16),

Title: A Spotlight on Inventor Junho Chung: Pioneering Innovations in Antibody Therapy

Introduction

Junho Chung is a prominent inventor based in Seongnam-si, Korea, known for his significant contributions to the field of biomedicine. With an impressive portfolio of 17 patents, he has made remarkable strides in the development of innovative therapies aimed at treating various health disorders.

Latest Patents

Among Junho Chung's latest inventions are two groundbreaking patents that have garnered attention for their potential therapeutic applications. The first patent, titled "Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof," encompasses antibodies specifically designed to target human FAM19A5. This innovation has the potential to modulate FAM19A5 activity, offering avenues for treating conditions such as central nervous system damage and degenerative brain disorders by inhibiting excessive proliferation of reactive astrocytes.

The second patent, "PDGF receptor antibody and use thereof," relates to an antibody targeting the PDGF receptor. This invention is transformative as it introduces an antibody-drug conjugate that links a chemotherapeutic agent to the antibody. Such an approach shows promise for the prevention or treatment of ocular neovascular diseases, indicating Chung's commitment to advancing therapeutic options for complex medical challenges.

Career Highlights

Junho Chung's career has seen him contributing to renowned institutions, including Seoul National University and Neuracle Science Co., Ltd. His work at these organizations has positioned him at the forefront of research and development within the biomedical field, allowing him to blend academic inquiry with practical applications.

Collaborations

Collaboration is key to innovation, and Chung has worked alongside notable professionals such as Hyori Kim and Junyeong Jin. These partnerships emphasize the importance of teamwork in driving forward-thinking projects and enhancing the scope of their research endeavors.

Conclusion

Junho Chung's groundbreaking patents and collaborative spirit exemplify the essence of innovation in the biomedical field. His work not only contributes to scientific advancement but also holds the potential to improve patient outcomes for those suffering from various disorders. As he continues to drive innovation, the impact of his inventions will undoubtedly be felt across the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.